Using Adebrelimab with chemotherapy and possibly chest radiotherapy for extensive stage small cell lung cancer
A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Hebei Medical University Fourth Hospital · NCT06323265
This study is testing if adding Adebrelimab to chemotherapy and possibly chest radiotherapy can help people with extensive stage small cell lung cancer feel better and improve their treatment results.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hebei Medical University Fourth Hospital (other) |
| Drugs / interventions | Adebrelimab, chemotherapy |
| Locations | 1 site (Shijiazhuang, Hebei) |
| Trial ID | NCT06323265 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness and safety of Adebrelimab when combined with chemotherapy and, if applicable, chest radiotherapy in patients diagnosed with extensive stage small cell lung cancer. It focuses on real-world outcomes, assessing how this treatment regimen performs outside of controlled clinical settings. The study aims to gather data on patient responses and any adverse effects experienced during treatment.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with confirmed extensive stage small cell lung cancer and normal organ function.
Not a fit: Patients with serious uncontrolled health conditions or significant drug allergies may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a new first-line treatment option for patients with extensive stage small cell lung cancer.
How similar studies have performed: While this specific combination has not been extensively tested in prior studies, similar approaches in treating small cell lung cancer have shown promise.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age:≥18 years old; 2. Patients with extensive stage small cell lung cancer confirmed by histopathology; 3. Normal function of major organs; 4. Participants were willing to join in this study, and written informed consent, good adherence, cooperate with the follow-up. Exclusion Criteria: 1. Patients with drug allergy sufferers; 2. Serious and uncontrolled organic lesions or infections, such as decompensated heart, lung, kidney failure, etc; 3. History of psychiatric drugs abuse and can't quit or patients with mental disorders; 4. The researchers think inappropriate.
Where this trial is running
Shijiazhuang, Hebei
- Jun Wang — Shijiazhuang, Hebei, China (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Extensive Stage Small Cell Lung Cancer